Scleroderma Treatment With Autologous Transplant (STAT) Study
Condition: Systemic Scleroderma
Interventions: Biological: Anti-Thymocyte Globulin; Procedure: Autologous Hematopoietic Stem Cell Transplantation; Drug: Cyclophosphamide; Biological: Filgrastim; Other: Laboratory Biomarker Analysis; Drug: Mycophenolate Mofetil; Procedure: Peripheral Blood Stem Cell Transplantation; Drug: Plerixafor; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2017
Interventions: Biological: Anti-Thymocyte Globulin; Procedure: Autologous Hematopoietic Stem Cell Transplantation; Drug: Cyclophosphamide; Biological: Filgrastim; Other: Laboratory Biomarker Analysis; Drug: Mycophenolate Mofetil; Procedure: Peripheral Blood Stem Cell Transplantation; Drug: Plerixafor; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2017